PROQINASE GMBH PURCHASED BY REACTION BIOLOGY CORPORATION
On February 4, 2019 Reaction Biology Corporation (RBC) (www.reactionbiology.com) and ChinaEquity Group (CEG) (www.chinaequity.net) announced the completion of a stock swap transaction where by RBC has aquired all the shares of ProQinase GmbH.
The combination of RBC and ProQinase will create the world’s leading kinase drug discovery company, with a diverse offering and operations in Europe and the United States. The combined companies plan to continue expanding operations in both facilities and adding to their product offerings. In addition, RBC plans to open a China-based subsidiary in collaboration with its significant new shareholder, CEG.